E
SELLAS Life Sciences Group, Inc. SLS
$1.41 $0.0050.36% NASDAQ
Recommendation
Prev Close
$1.40
Volume
2,286,093
Avg Vol (90D)
2,145,252
Market Cap
$127.19M
Dividend & Yield
--
52-Week Range
$0.772 - $1.84
P/E (TTM)
--
EPS (TTM)
-$0.5387
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
SELLAS Life Sciences (SLS) Reports Promising Preclinical Results for SLS009 in Leukemia SLS ...
4/28/2025 - GuruFocus
Sellas Life Sciences announces preclinical data of SLS009 in AML
4/28/2025 - The Fly
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference
4/28/2025 - Globe Newswire
SELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher - Time to Buy?
4/26/2025 - MarketBeat
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
4/23/2025 - Globe Newswire
SELLAS Life Sciences (SLS) Shares Surge on Promising Trial Results
4/8/2025 - GuruFocus
Sellas Life Sciences Shares Gains On Positive Cohort 3 Phase 2 Results For SLS009
4/8/2025 - RTT News - Momentum Stocks
Sellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trial
4/8/2025 - TipRanks Financial Blog
Sellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trial
4/8/2025 - The Fly
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML
4/8/2025 - Globe Newswire
Head-To-Head Review: SELLAS Life Sciences Group (NASDAQ:SLS) & CV Sciences (OTCMKTS:CVSI)
4/3/2025 - Ticker Report
Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst
3/31/2025 - SeekingAlpha
Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst
3/31/2025 - Seeking Alpha - Long Ideas
Sellas Life Sciences Advances in Cancer Treatment Development
3/27/2025 - TipRanks Financial Blog
SELLAS Life Sciences Group (NASDAQ:SLS) Issues Quarterly Earnings Results
3/21/2025 - MarketBeat
Brooklyn FI LLC Takes Position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)
3/21/2025 - MarketBeat
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update
3/20/2025 - GuruFocus
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update
3/20/2025 - Globe Newswire
SELLAS Life Sciences Group (SLS) to Release Earnings on Thursday
3/20/2025 - MarketBeat
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Decrease in Short Interest
3/7/2025 - MarketBeat
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Down 11.8% in February
3/7/2025 - Ticker Report
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025
2/27/2025 - PR Newswire
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025
2/27/2025 - CNW Group - News Releases
SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial
2/20/2025 - Seeking Alpha - Healthcare
Sellas Life Sciences' zanubrutinib combination shows efficacy in DLBCL
2/20/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$32.61M
Net Income (TTM)
-$30.88M
Balance Sheet
Total Assets (Q)
$19.43M
Total Debt (Q)
$1.00M
Total Liabilities (Q)
$9.97M
Book Value Per Share (Q)
$0.1279
Cash Flow
Cash from Operations (TTM)
-$35.40M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$46.76M
Net Change in Cash (TTM)
$11.36M
Filings
Filing Date
Thursday, March 20, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.62
7-Day Total Return
10.16%
30-Day Total Return
23.68%
60-Day Total Return
6.02%
90-Day Total Return
61.68%
Year to Date Total Return
31.78%
1-Year Total Return
-3.42%
2-Year Total Return
-3.42%
3-Year Total Return
-52.20%
5-Year Total Return
-28.79%
52-week Low
Dec 13, 2024 - $0.772
52-week High
Feb 03, 2025 - $1.84
Valuation
Market Cap
$127.19M - Micro Cap
Enterprise Value
$114.30M
Price/Sales (TTM)
--
Price/Book (Q)
10.95
Dividends and Shares
Shares Outstanding
73.99M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.sellaslifesciences.com
Phone Number
646 200 5278
Address
7 Times Square
New York, NY 10036
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The... more
NASDAQ 04/28/2025 12:31PM Eastern Quotes delayed